DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

2014
INDEX
Compound 48/80, histamine and, 914
COMT. See Catechol-Omethyltransferase
(COMT);
Catechol-Omethyltransferase
(COMT)
Concentration
peak
of common drugs, 1809t–1890t
as pharmacodynamic parameter,
1805–1806
time to peak, as pharmacodynamic
parameter, 1804–1805
Condoms, one-year failure rate, 1834t
Conduction
axonal, 182–183
definition of, 182
Condylomata acuminata, 1818
Confusion, in prescription writing,
1880–1881
Congenital adrenal hyperplasia (CAH)
and hirsutism, 1840
treatment of, 1231–1232
Congenital chlorine losing diarrhea,
102t
Congenital hypothyroidism, 1145
Congenital secretory diarrhea, 102t
Congestive heart failure, 789–813. See
also Heart failure
angina pectoris with, recommended
treatment for, 769t
clinical summary, 808–810
definition of, 789–790
diastolic, 805–806, 806f
epidemiology, 789
mortality rate for, 789
nitrates for, 760
prevention, 808
stages of, 808, 809f
systolic, vascular dysfunction in, as
therapeutic target, 806–807
treatment of
goals, 807f
and normal vascular reactivity,
807f
Conivaptan, 714, 716t
drug interactions with, 717
pharmacokinetics of, 714
Conjugating enzymes, 131–139
Conjunctiva
bulbar, 1773
palpebral, 1773
systemic agents affecting, 1793
Conjunctivitis
allergic, H 1
receptor antagonists for,
922
Conjunctivitis (Cont.):
fungal, 1784t
parasitic, 1783
yeast, 1784t
Connective-tissue disorders (CTD),
IVIG for, 1827
Conservation, evolutionary, 155
Constipation
dietary fiber and, 1330–1331
opioid antagonists and, 515
with opioids, 1335
pathophysiology of, 1329
treatment of, 1328–1336
Constitutive androstane receptor
(CAR), 97, 140t, 141
Contact dermatitis, H 1
receptor
antagonists for, 922
Contraception, 1833–1837. See also
Oral contraceptives
administration, 1833
choice of, 1188–1189
emergency, 1836t
definition of, 1833
female, oral agents for (See Oral
contraceptives)
hormonal, 1185–1189
male, 1204 (See also Vasectomy)
noncontraceptive benefits, 1834
one-year failure rates, by type, 1834t
planned, 1833–1836
definition of, 1833
postcoital, 1837
transdermal patch for, 1834
Contraceptives, oral, polymorphisms
and response to, 161t
Controlled-release preparations, 21
Controlled Substances Act (CSA),
1881
Controlled substance schedules, 1882t
Coolants, for pruritus, 1828t
Copper, 1085–1086
Copper antidote, 86t
Copy number variations (CNVs), 147f,
148
CORDARONE (amiodarone), 834
CORDRAN (flurandrenolide), 1225t
CORDRAN SP (flurandrenolide cream),
1225t
COREG (carvedilol), 801
Cornea, 1774–1775, 1776f
endothelium, 1774–1775
epithelium, 1774–1775
stroma, 1774–1775
systemic agents affecting, 1793
ulcers, bacterial, treatment of, 1781t
Cornea verticillata, 1793
Coronary arteries
alpha adrenergic receptors in, 203t
in autonomic nervous system, 178t
Coronary artery bypass grafting, 753
Coronary heart disease, 751
prevention of, 887–889
Coronary heart disease (CHD), 877
premature, family history of, and
risk for coronary heart
disease, 887t
risk assessment, guidelines for
(NCEP), 885–887
risk category, treatment based on,
886t
risk factors for, 884–885, 887t
Coronary revascularization patients,
dyslipidemia treatment in,
890
Corticosteroids
for lung disease, 1046–1052
relative potencies and equivalent
doses of, 1216t
therapeutic uses of, for
inflammatory bowel disease,
1352t
Corticotropin-releasing hormone
(CRH), stimulation test,
1214–1215
Corticotropin releasing hormone
receptor polymorphism, 160t
Cortisol (hydrocortisone)
relative potencies and equivalent
doses of, 1216t
structure-activity relationships of,
1216t
Cortisone, relative potencies and
equivalent doses of, 1216t
CORVERT (ibutilide), 841
Cosmopolitan polymorphisms, 150
COSOPT (dorzolamide hydrochloride),
1787
Costs
of development, 14f
of drugs, 11
Co-transmission, in autonomic system,
213–214
Co-transporters, 95
Couarmin antidote, 86t
Cough, ACE inhibitors and, 735–736
Cough reflex, 496
Coumarin, 849
COVERA-HS (verapamil), 831
Coxibs, 937, 964–965, 990–992
COZAAR (losartan), 738